Testosterone Therapy Monitoring and DHEA Recommendations for Women

Testosterone Monitoring Protocol

Obtain a baseline serum total testosterone level before initiating therapy to establish the patient’s starting point and guide dose adjustments. 1
Re‑measure total testosterone 3–6 weeks after starting treatment to verify that levels are within the physiologic premenopausal female range and to detect early over‑exposure. 4
Continue serum total testosterone testing every 6 months for long‑term surveillance of androgen excess, dose adequacy, and potential over‑use. 4

Aim to keep serum total testosterone within the normal premenopausal female range (i.e., avoid supraphysiologic concentrations). The guideline emphasizes physiological rather than numeric targets, discouraging levels that exceed typical female values. 5

Do not use supraphysiologic testosterone preparations such as high‑dose pellets or injectable regimens, because they risk androgen excess and are not endorsed by the guideline. 5
If no clinical benefit is observed by 6 months, discontinue testosterone therapy to avoid unnecessary exposure. 5
Screen regularly for signs of androgen excess (e.g., hirsutism, acne, voice deepening) as part of routine follow‑up. 4

Systemic DHEA supplementation is not recommended for postmenopausal women with normal adrenal function and should not be used for hypoactive sexual desire disorder. This is a Level IA, Grade A recommendation reflecting strong evidence of lack of efficacy. 5
The Endocrine Society concurs, advising against routine DHEA use in women because indications are insufficient and data on efficacy and long‑term safety are lacking. 4

Off‑label use of male testosterone formulations is permissible only when serum concentrations are strictly maintained within the physiologic female range and monitored appropriately. 5
Compounded “bioidentical” testosterone products should not be used unless no FDA‑approved preparation is available, due to absent efficacy and safety data. 5
Routine diagnostic measurement of testosterone in women is discouraged, as symptom‑level correlations have not been validated. 4